Navigation Links
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Date:2/6/2009

d for the treatment of schizophrenia in the E.U. If approved, Janssen will also market paliperidone palmitate.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a subsidiary of Johnson & Johnson, the world's most broadly-based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com.

Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is based in Titusville, N.J. and is the only large pharmaceutical company in the U.S. dedicated solely to mental health. It currently markets prescription medications for the treatment of schizophrenia, bipolar mania and the treatment of symptoms associated with autistic disorder. For more information about Janssen, visit http://www.janssen.com.

IMPORTANT SAFETY INFORMATION FOR INVEGA

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Paliperidone is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with paliperidone and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

One ri
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
(Date:10/30/2014)... Oct. 30, 2014   Auxilium Pharmaceuticals , ... integrated specialty biopharmaceutical company, today announced financial results ... The Company highlighted important corporate, commercial, regulatory and ... "We are very pleased with the continued ... products in our portfolio this quarter, especially the ...
(Date:10/30/2014)... 30, 2014 Today, DripDrop, the first ... it was awarded a two-year contract, effective Sept. ... that serves the more than 100,000 members and ... and Provista.  DripDrop also received ... member hospitals who attended the recent Novation 2014 ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... synthetic immunogens against cancers and infectious diseases, announced today ... Development Agreement (CRADA) with the United States Department of ... Animal Disease Center. This collaboration will evaluate the efficacy ...
... Co., Inc. (NYSE Amex: TPI ), a pharmaceutical ... branded generics and other pharmaceuticals, announced the financial results for ... year 2011 ending June 30 ... delivered $95.2 million, exceeding the guided $90.0 million revenue forecast ...
Cached Medicine Technology:Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4TPI Reports Fiscal Year 2011 Financial Results 2TPI Reports Fiscal Year 2011 Financial Results 3TPI Reports Fiscal Year 2011 Financial Results 4TPI Reports Fiscal Year 2011 Financial Results 5TPI Reports Fiscal Year 2011 Financial Results 6TPI Reports Fiscal Year 2011 Financial Results 7TPI Reports Fiscal Year 2011 Financial Results 8TPI Reports Fiscal Year 2011 Financial Results 9TPI Reports Fiscal Year 2011 Financial Results 10TPI Reports Fiscal Year 2011 Financial Results 11
(Date:10/31/2014)... are clear differences in the brains of people with ... new research indicates. Scientists at Stanford University ... diagnose this baffling condition and shed light on how ... misdiagnosed or labeled as hypochondriacs. Using three ... [chronic fatigue syndrome] patients, brains diverge from those of ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. ... to appear in the United States, a new U.S. government ... the United States each year, researchers at the U.S. Centers ... 250,000 cases that occurred worldwide in 2008, according to the ... disease that causes skin sores, nerve damage, and muscle weakness ...
(Date:10/31/2014)... By Steven Reinberg HealthDay ... skin condition eczema may increase slightly the risk of broken bones ... of 34,500 adults, researchers found that among 7 percent of people ... had a bone or joint injury and 0.6 percent had an ... people without eczema, those with the skin condition had more than ...
(Date:10/30/2014)... NY)—Investigators at Albert Einstein College of Medicine ... Center will present their latest aging research ... Annual Scientific Meeting. Topics include the identification of ... for cognitive impairment and the cellular biology of ... 2014 in Washington, D.C., "Einstein-Montefiore has distinguished itself ...
(Date:10/30/2014)... at least 2 years old to be covered by ... guidance exists other than the general recommendation by national ... least the first six months. , So what ... that motivated researchers at the University at Buffalo School ... patterns of American infants at 6 months and 12 ...
Breaking Medicine News(10 mins):Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3Health News:Leprosy Still Occurs in U.S., CDC Reports 2Health News:Leprosy Still Occurs in U.S., CDC Reports 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3
... , New research reveals that a persons socioeconomic status ... After reviewing 20 years of medical literature regarding the ... adults, researchers from LDS Hospital and the University of ... correlation between the two, even after adjusting for smoking ...
... 2007 - Oakland, CA Childrens Hospital & Research ... $9 million funding award from the National Institutes of ... in collaboration with Children,s Hospital Oakland Research Institute, was ... which supports innovative hands-on programs that encourage children to ...
... Tobacco Cessation,Campaign, HARRISBURG, Pa., Nov. 13 As ... eight residents,who are willing to document their attempts to ... Cancer Society,s annual event, held on the third Thursday,in ... the hope that they will,stop using tobacco for good., ...
... BASKING RIDGE, N.J., Nov. 13 Millennium,Biotechnologies ... Bulletin Board: MBTG), today announced that it had ... exclusive provider of,nutritional products to Provider Services Inc. ... with PSI purchasing Millennium,s,Resurgex Select(TM) line of products. ...
... End of 2007 and the Rest by Q1 2008., ... Active Directory Tasks and ... 13 Chip PC industry-leading,thin client solutions were chosen ... of North Rhine-Westphalia County to,supply 20,000 thin clients and ...
... 13 Cardinal Health today,announced an exclusive alliance ... helps eligible health care facilities implement,manage and meet ... Pricing Program. The 340B Drug Pricing Program ... federally qualified health care facilities provide care,for the ...
Cached Medicine News:Health News:National Institutes of Health selects Children's Hospital Oakland for grant award 2Health News:State Health Officials Seek Quitters as Part of Great American Smokeout 2Health News:Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio 2Health News:Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio 3Health News:Chip PC Wins Europe's Largest Thin Client Tender to Supply 20,000 Thin Clients and Management Software to German RZF - Financial Administration of North Rhine-Westphalia County 2Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 2Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 3Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: